Climb Bio, Inc. — Director's Dealing 2021

Aug 10, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2021-08-09

Reporting Person: Bucher James B (EVP and General Counsel)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.32	2031-02-25	Common Stock (130661)		Direct
Stock Option (Right to Buy)	$6.10	2031-04-26	Common Stock (67749)		Direct

Footnotes

F1: The shares subject to this option shall vest at a rate of 12/48ths of the total number of shares on the one-year anniversary of October 1, 2020 (the "October 2020 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the October 2020 Vesting Commencement Date thereafter (or if there is no corresponding day, on the last day of the month) for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the October 2020 Vesting Commencement Date.

F2: The shares subject to this option shall vest at a rate of 12/48ths of the total number of shares on the one-year anniversary of April 27, 2021 (the "April 2021 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the April 2021 Vesting Commencement Date thereafter (or if there is no corresponding day, on the last day of the month) for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the April 2021 Vesting Commencement Date.